| Company Name: |
Shanghai Hanhong Scientific Co.,Ltd.
|
| Tel: |
021-54306202 13764082696 |
| Email: |
info@hanhongsci.com |
| Products Intro: |
Product Name:(D-Lys(nicotinoyl)1,β-(3-pyridyl)-Ala3,3,4-dichloro-D-Phe5,Asn6,D-Trp7·9,Nle11)-Substance P
CAS:129176-97-2
Remarks:303P10
|
|
| | spantide II Basic information |
| Product Name: | spantide II | | Synonyms: | (D-Lys(nicotinoyl)1,b-(3-pyridyl)-Ala3,3,4-dichloro-D-Phe5,Asn6,D-Trp7·9,Nle11)-Substance P;H-D-Lys(nicotinoyl)-Pro-b-(3-pyridyl)-Ala-Pro-3,4-dichloro-D-Phe-Asn-D-Trp-Phe-D-Trp-Leu-Nle-NH2;L-Norleucinamide, N6-(3-pyridinylcarbonyl)-D-lysyl-L-prolyl-3-(3-pyridinyl)-L-alanyl-L-prolyl-3,4-dichloro-D-phenylalanyl-L-asparaginyl-D-tryptophyl-L-phenylalanyl-D-tryptophyl-L-leucyl-;(D-Lys(nicotinoyl)1,β-(3-pyridyl)-Ala3,3,4-dichloro-D-Phe5,Asn6,D-Trp7·9,Nle11)-Substance P;(D-Lys(nicotinoyl)1,β-(3-pyridyl)-Ala3,3,4-dichloro-D-Phe?,Asn?,D-Trp?·?,Nle11)-Substance P trifluoroacetate salt;(D-Lys(nicotinoyl)?,β-(3-pyridyl)-Ala?,3,4-dichloro-D-Phe?,Asn?,D-Trp?·?,Nle??)-Substance P trifluoroacetate salt;(D-Lys(nicotinoyl)1,b-(3-pyridyl)-Ala3,3,4-dichloro-D-Phe5,Asn6,D-Trp7·9, Nle 11)-Substance P trifluoroacetate salt;(D-Lys(nicotinoyl)1,β-(3-pyridyl)-Ala3 | | CAS: | 129176-97-2 | | MF: | C86H104Cl2N18O13 | | MW: | 1668.79 | | EINECS: | | | Product Categories: | | | Mol File: | 129176-97-2.mol |  |
| | spantide II Chemical Properties |
| form | Lyophilized solid. | | color | White to off-white |
| | spantide II Usage And Synthesis |
| Uses | Spantide II, an undecapeptide substance P (SP) analog, is a potent neurokinin-1 receptor (NK-1R) antagonist. Spantide II binds with NK-1R and blocks proinflammatory activities associated with SP. Spantide II can be used in the research of inflammatory skin disorders, such as psoriasis and contact dermatitis[1][2][3]. | | IC 50 | NK1 | | References | [1] Xu XJ, et al. Spantide II, a novel tachykinin antagonist, and galanin inhibit plasma extravasation induced by antidromic C-fiber stimulation in rat hindpaw. Neuroscience. 1991;42(3):731-7. DOI:10.1016/0306-4522(91)90041-l
[2] Kikwai L, et al. In vitro and in vivo evaluation of topical formulations of spantide II. AAPS PharmSciTech. 2005 Oct 31;6(4):E565-72. DOI:10.1208/pt060471
[3] Babu RJ, et al. Percutaneous absorption and anti-inflammatory effect of a substance P receptor antagonist: spantide II. Pharm Res. 2004 Jan;21(1):108-13. DOI:10.1023/b:pham.0000012157.80716.73 |
| | spantide II Preparation Products And Raw materials |
|